Eiger BioPharmaceuticals, Inc. (EIGRQ)
OTCMKTS
· Delayed Price · Currency is USD
8.50
0.00 (0.00%)
Inactive · Last trade price
on Oct 1, 2024
Eiger BioPharmaceuticals Revenue
In the year 2023, Eiger BioPharmaceuticals had annual revenue of $15.77M with 16.98% growth. Eiger BioPharmaceuticals had revenue of $-609.80K in the quarter ending June 30, 2024, a decrease of -114.81%.
Revenue
15.77M
Revenue Growth
+16.98%
P/S Ratio
0.80
Revenue / Employee
630.92K
Employees
25
Market Cap
12.59M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 920.97M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 108.78M |
Eiger BioPharmaceuticals News
- 6 months ago - Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar - Reuters